FMP
Aprea Therapeutics, Inc.
APRE
NASDAQ
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
5.35 USD
-0.49 (-9.16%)
About
ceo
Dr. Oren Gilad Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://atrinpharma.com
exchange
NASDAQ
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
CIK
0001781983
ISIN
US03836J2015
CUSIP
03836J102
Address
535 Boylston St.
Phone
617-463-9385
Country
US
Employee
7
IPO Date
Oct 3, 2019
Key Executives
